![](/wp-content/uploads/2022/01/Blast-Covers-1.png)
$599
FDA Approves Lannett’s Bs-glargine IND; Biocon CY Q4 ’21 (FY Q3 ’22) Earnings Update
Two cardiometabolic-related news items have been observed: Lannett announced FDA has approved the IND application for Lannett’s bs-glargine; and Biocon hosted its Q4 ’21 (FY Q3 ’22) earnings call (press release). Below, FENIX provides highlights and insights for the respective new items.